stockrow
Saturday 7 November 2026
Export XFOR’s income statement to Excel — free account
X4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.
- Revenue
- +63.1%
- EPS
- +76.9%
- Free cash flow
- +27.5%
- Total debt
- +1.24%
Quarter to September 2026, against a year earlier
3.15
0.08
+2.61%
Follow XFOR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
21.63 | 37.23 | 57.86 | 4.82 | |
P/FCF ratio |
15.56 | 37.02 | 59.10 | 10.54 | |
P/Operating CF |
(18.18) | (28.38) | (26.61) | (10.90) | |
P/B ratio |
2.64 | 3.80 | 3.10 | 0.91 | |
Price to Tangible BV |
3.38 | 4.72 | 3.67 | 1.06 | |
EV/Sales |
15.15 | 29.00 | 40.51 | (0.19) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.08 | |
EV/Operating CF |
(3.38) | (5.49) | (3.93) | 0.08 | |
EV/FCF |
10.90 | 28.84 | 41.38 | (0.42) | |
Quick Ratio |
12.62 | 10.84 | 9.88 | 9.84 | |
Current Ratio |
13.22 | 11.30 | 10.18 | 10.16 | |
Net Debt/EBITDA |
5.63 | 8.52 | 7.83 | 7.53 | |
Debt/Assets |
33.22% | 30.33% | 28.31% | 26.27% | |
Debt/Equity |
0.55 | 0.49 | 0.45 | 0.41 | |
Asset Turnover |
0.09 | 0.09 | 0.05 | 0.16 | |
Operating CF/Net income |
1.00 | 1.29 | 0.97 | 0.65 | |
Capex/Depreciation |
0.00 | (5.01) | 0.00 | 0.00 | |
Interest Coverage |
(9.11) | (7.57) | (9.52) | (10.84) | |
Research and Development Expense of Revenue |
463.46% | 171.24% | 570.53% | 721.22% | |
Selling, General and Administrative Expense of Revenue |
313.09% | 96.54% | 257.24% | 287.46% | |
Intangible Assets out of Total Assets |
0.13 | 0.12 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
121.67% | 35.04% | 89.11% | 88.43% | |
Graham Net Nets |
0.29 | 0.21 | 0.27 | 0.93 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.09%) | (25.70%) | (109.93%) | (108.50%) | |
Free Cash Flow Yield |
6.42% | 2.70% | 1.69% | 9.49% | |
Revenue per Share |
0.02 | 0.07 | 0.02 | 0.06 | |
Operating CF per Share |
(0.16) | (0.16) | (0.16) | (0.37) | |
Capex per Share |
0.00 | (0.04) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.20) | (0.16) | (0.37) | |
Cash per Share |
1.48 | 1.65 | 1.85 | 5.98 | |
Shareholders Equity per Share |
1.10 | 1.23 | 1.33 | 4.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.10 | 1.23 | 1.33 | 4.40 | |
Free Cash Flow |
(20.19) | (25.79) | (19.60) | (15.53) | |
Working Capital |
183.15 | 199.49 | 218.21 | 235.82 | |
Capital Expenditures |
0.00 | (5.00) | — | 0.00 | |
Net Current Asset Value |
105.20 | 121.25 | 140.15 | 157.41 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.08 | |
Capex to Sales |
0.00 | 0.57 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.54 | 1.96 | 1.14 | 1.14 | |
Average Payables |
4.97 | 5.82 | 8.09 | 7.16 | |
Average Inventory |
4.79 | 4.34 | 3.86 | 3.65 | |
Average Assets |
197.69 | 179.12 | 200.15 | 218.45 | |
Average Common Equity |
100.25 | 79.71 | 95.70 | 104.22 |
Columns are period end dates · fundamentals updated 6 Nov 2026